Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PTCTNASDAQ:RYTMNASDAQ:SNDXNASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePTCTPTC Therapeutics$46.75+0.8%$48.62$28.72▼$58.38$3.71B0.52859,293 shs1.24 million shsRYTMRhythm Pharmaceuticals$57.28+0.9%$57.30$35.17▼$68.58$3.64B2.36550,767 shs666,729 shsSNDXSyndax Pharmaceuticals$9.28-8.9%$12.33$9.24▼$25.07$798.52M0.821.70 million shs3.22 million shsSRPTSarepta Therapeutics$35.74-1.3%$62.68$34.90▼$173.25$3.51B0.851.68 million shs5.21 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePTCTPTC Therapeutics+0.78%+14.77%+3.70%-5.88%+49.94%RYTMRhythm Pharmaceuticals+0.86%-11.12%-4.76%-0.49%+41.85%SNDXSyndax Pharmaceuticals-8.93%-7.11%-17.44%-38.46%-57.16%SRPTSarepta Therapeutics-1.27%-2.67%-34.58%-67.35%-73.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationPTCTPTC Therapeutics4.2528 of 5 stars4.33.00.04.42.50.80.0RYTMRhythm Pharmaceuticals4.1114 of 5 stars4.51.00.04.32.10.80.6SNDXSyndax Pharmaceuticals3.8675 of 5 stars4.51.00.04.42.80.00.0SRPTSarepta Therapeutics4.7012 of 5 stars4.42.00.04.21.82.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePTCTPTC Therapeutics 2.67Moderate Buy$61.9232.46% UpsideRYTMRhythm Pharmaceuticals 3.00Buy$75.3831.61% UpsideSNDXSyndax Pharmaceuticals 2.91Moderate Buy$35.91286.95% UpsideSRPTSarepta Therapeutics 2.83Moderate Buy$126.74254.61% UpsideCurrent Analyst Ratings BreakdownLatest SNDX, RYTM, PTCT, and SRPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$55.00 ➝ $68.005/8/2025PTCTPTC TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.005/8/2025SRPTSarepta TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy$188.00 ➝ $85.005/8/2025SRPTSarepta TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$115.00 ➝ $100.005/8/2025SRPTSarepta TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Inline$50.005/7/2025PTCTPTC TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$57.00 ➝ $58.005/7/2025PTCTPTC TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$70.00 ➝ $66.005/7/2025PTCTPTC TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$113.00 ➝ $112.005/7/2025PTCTPTC TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $67.005/7/2025PTCTPTC TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSell ➝ Neutral$50.00 ➝ $40.005/7/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$66.00 ➝ $72.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPTCTPTC Therapeutics$1.77B2.09$2.25 per share20.80($10.85) per share-4.31RYTMRhythm Pharmaceuticals$136.86M26.63N/AN/A$2.87 per share19.96SNDXSyndax Pharmaceuticals$43.72M18.26N/AN/A$6.53 per share1.42SRPTSarepta Therapeutics$2.23B1.57N/AN/A$9.19 per share3.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePTCTPTC Therapeutics-$626.60M$6.51N/AN/AN/A-50.32%N/A-16.44%N/ARYTMRhythm Pharmaceuticals-$184.68M-$2.81N/AN/AN/A-230.07%-367.36%-77.47%N/ASNDXSyndax Pharmaceuticals-$209.36M-$3.86N/AN/AN/AN/A-64.34%-57.72%N/ASRPTSarepta Therapeutics-$535.98M-$2.6928.593.27N/A7.43%11.00%3.35%N/ALatest SNDX, RYTM, PTCT, and SRPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025RYTMRhythm Pharmaceuticals-$0.69-$0.81-$0.12-$0.81$40.43 million$37.72 million5/6/2025Q1 2025PTCTPTC Therapeutics$0.85$10.04+$9.19N/A$437.16 million$1.18 billion5/6/2025Q1 2025SRPTSarepta Therapeutics$2.20-$3.42-$5.62-$4.60$685.75 million$744.86 million5/5/2025Q1 2025SNDXSyndax Pharmaceuticals-$1.04-$0.98+$0.06-$0.98$15.88 million$20.04 million3/3/2025Q4 2024SNDXSyndax Pharmaceuticals-$0.31-$1.10-$0.79-$1.10$86.32 million$7.68 million2/26/2025Q4 2024RYTMRhythm Pharmaceuticals-$0.69-$0.72-$0.03-$0.72$38.48 million$41.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPTCTPTC TherapeuticsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPTCTPTC TherapeuticsN/A2.102.04RYTMRhythm PharmaceuticalsN/A3.493.34SNDXSyndax PharmaceuticalsN/A6.996.99SRPTSarepta Therapeutics0.933.843.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPTCTPTC TherapeuticsN/ARYTMRhythm PharmaceuticalsN/ASNDXSyndax PharmaceuticalsN/ASRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipPTCTPTC Therapeutics5.50%RYTMRhythm Pharmaceuticals5.60%SNDXSyndax Pharmaceuticals4.10%SRPTSarepta Therapeutics7.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePTCTPTC Therapeutics1,41079.26 million72.88 millionOptionableRYTMRhythm Pharmaceuticals14063.62 million58.02 millionOptionableSNDXSyndax Pharmaceuticals11086.05 million81.86 millionOptionableSRPTSarepta Therapeutics84098.28 million88.17 millionOptionableSNDX, RYTM, PTCT, and SRPT HeadlinesRecent News About These CompaniesBearish: Analysts Just Cut Their Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Revenue and EPS estimatesMay 14 at 9:11 AM | finance.yahoo.comPharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore (SRPT)May 14 at 8:30 AM | marketbeat.comEnsign Peak Advisors Inc Has $21.10 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 14 at 5:26 AM | marketbeat.comSarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular DystrophyMay 13 at 6:07 PM | finance.yahoo.comJ. Goldman & Co LP Purchases 8,628 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 13 at 8:22 AM | marketbeat.comJanus Henderson Group PLC Sells 30,188 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 13 at 8:05 AM | marketbeat.com2 Stocks Near Their 52-Week Lows That Still Aren't Worth BuyingMay 13 at 4:14 AM | fool.comSarepta Therapeutics, Inc. (SRPT): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside PotentialMay 12 at 10:30 PM | finance.yahoo.comSarepta Therapeutics, Inc. (SRPT): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside PotentialMay 11, 2025 | insidermonkey.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Holdings Lifted by Farallon Capital Management LLCMay 11, 2025 | marketbeat.comBokf Na Acquires 11,990 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 11, 2025 | marketbeat.comStifel Financial Corp Decreases Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 11, 2025 | marketbeat.comRep. Gilbert Ray Cisneros, Jr. Sells Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 11, 2025 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Stock Rating Lowered by Evercore ISIMay 10, 2025 | marketbeat.comFred Alger Management LLC Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 10, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTMay 10, 2025 | accessnewswire.comWhy Sarepta Therapeutics, Inc.’s (SRPT) Stock Is Up 6.43%May 10, 2025 | aaii.comBalyasny Asset Management L.P. Sells 218,359 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 10, 2025 | marketbeat.comRep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 10, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Price Target Cut to $125.00 by Analysts at Needham & Company LLCMay 10, 2025 | americanbankingnews.comSarepta Therapeutics Target of Unusually High Options Trading (NASDAQ:SRPT)May 10, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNDX, RYTM, PTCT, and SRPT Company DescriptionsPTC Therapeutics NASDAQ:PTCT$46.75 +0.36 (+0.78%) As of 05/14/2025 04:00 PM EasternPTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Rhythm Pharmaceuticals NASDAQ:RYTM$57.28 +0.49 (+0.86%) As of 05/14/2025 04:00 PM EasternRhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Syndax Pharmaceuticals NASDAQ:SNDX$9.28 -0.91 (-8.93%) As of 05/14/2025 04:00 PM EasternSyndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Sarepta Therapeutics NASDAQ:SRPT$35.74 -0.46 (-1.27%) As of 05/14/2025 04:00 PM EasternSarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
